)
)
Edge16 Oct 2026
Winner, Winner: The Chicken McNugget Story
How a 1940s breeding contest, a Cornell food scientist, and a hedge by Ray Dalio helped McDonald's turn the Chicken McNugget into a fast-food icon.
Rani Therapeutics
Rani Therapeutics (RANI) investor relations material
Rani Therapeutics Q3 2026 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2026 earnings summary9 Nov, 2026
Executive summary
RT-114 Phase 1a single-dose data showed oral bioavailability above 150% versus matched subcutaneous dosing; no serious adverse events or events attributed to the capsule were reported.
The RaniPill platform entered the FDA Emerging Technology Program in October 2026; participation supports technical, manufacturing and regulatory discussions, but is not approval.
Partnerships with Chugai, ProGen and PegBio support programs in rare disease, immunology and obesity.
Financial highlights
Q3 contract revenue was $1.7M, all from Chugai, versus $0 in Q3 2025; 9M revenue was $5.1M versus $0.2M.
Q3 operating expenses rose 50.6% YoY to $10.9M; operating loss was $9.2M versus $7.3M and net loss was $8.8M versus $7.9M.
9M net loss narrowed to $25.2M from $31.9M and operating loss narrowed to $26.4M from $29.8M; net loss attributable to Class A holders rose to $22.2M from $19.4M.
Q3 stock-based compensation was $2.2M versus $2.3M.
Outlook and guidance
Cash, cash equivalents and marketable securities of $45.3M at September 30, 2026 are expected to fund operations through at least end-2027 under the current operating plan.
Operating losses and negative operating cash flows are expected to continue; substantial additional funding will be needed for development, clinical trials and manufacturing scale-up.
RT-114 Phase 1a expansion data are expected by year-end 2026; Phase 1b repeat-dose data in patients with obesity are anticipated in 2027.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Rani Therapeutics
- RT-114's Phase I PK supports a planned 2027 obesity data milestone.RANI
Chardan's 10th Annual Healthcare Conference - RaniPill's strong clinical data and major partnerships drive growth, with manufacturing and cash runway secured.RANIH.C. Wainwright 28th Annual Global Investment Conference
- RT-114 shows >150% oral bioavailability; Q2 revenue up, cash at $53.4M, risks persist.RANIQ2 2026
- Oral biologics platform shows >150% bioavailability in phase I-A, fueling major partnerships and pipeline growth.RANICanaccord Genuity's 46th Annual Growth Conference
- Directors elected, auditor ratified, and major partnerships and clinical milestones announced.RANIAGM 2026
- Net loss narrowed to $8.0M on $1.7M revenue, with cash runway into Q4 2027 and Nasdaq delisting risk.RANIQ1 2026
- Shareholders will vote on director elections and auditor ratification, with strong governance in place.RANIProxy filing
- Vote on board elections and auditor ratification at the May 28, 2026 annual meeting.RANIProxy filing
- Strong preclinical progress, reduced net loss, and RT-114 Phase 1 trial expected mid-2025.RANIQ4 2024
Next Rani Therapeutics earnings date
Q4 202625 Mar, 2027
Rani Therapeutics
Next Rani Therapeutics earnings date
Q4 202625 Mar, 2027
AI chat
Ask anything. Verify everything.
Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn moreFind what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.)
Trust every finding
50m+ first-party documents. Every output traceable to its source.Find what matters
AI across all first-party IR material. Live calls, transcripts, slides, filings.Trust every finding
50m+ first-party documents. Every output traceable to its source.Automations
Zero in on what matters
Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more)
Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.)
Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Event-triggered research
Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.Scheduled research
Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.Live audio & transcripts
Be first
Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more)
Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.)
Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Live earnings calls
Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.Live transcripts
Speaker-by-speaker, in real time. Searchable across every live and historical call.Quartr MCP connects your AI environment to 17K+ public companies
Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more
Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.
Jamie Ross
Investment Manager, GAM Investments
GAM
GAM
Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.
Tom O'Hara
Investment Director
Ciena
Ciena
Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.
Gregg Lampf
VP of Investor Relations
Protean
Protean
Being able to ask specific questions across years of transcripts and reports and instantly get verified answers is a game-changer.
Pontus Dackmo
CEO & Investment Manager
)
)
Frequently asked questions
Rani Therapeutics Holdings, Inc. is a clinical-stage biotherapeutics company primarily focused on the development of innovative technologies for the oral delivery of biologics. The company's flagship technology, the RaniPill capsule, represents a novel, proprietary platform designed to administer biologic drugs orally that would typically be delivered via injection. This technology aims to improve patient outcomes by making treatment more accessible and less invasive. Rani Therapeutics is exploring the potential of its platform across a range of drug substances, including peptides, proteins, and antibodies, with applications in various therapeutic areas. The company is headquartered in San Jose, California, and its shares are listed on the Nasdaq.